Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Insulin Biologics
1.2.3 Insulin Biosimilars
1.3 Market by Application
1.3.1 Global Insulin Biologics and Biosimilars Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Insulin Biologics and Biosimilars Market Perspective (2018-2029)
2.2 Insulin Biologics and Biosimilars Growth Trends by Region
2.2.1 Global Insulin Biologics and Biosimilars Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Insulin Biologics and Biosimilars Historic Market Size by Region (2018-2024)
2.2.3 Insulin Biologics and Biosimilars Forecasted Market Size by Region (2024-2029)
2.3 Insulin Biologics and Biosimilars Market Dynamics
2.3.1 Insulin Biologics and Biosimilars Industry Trends
2.3.2 Insulin Biologics and Biosimilars Market Drivers
2.3.3 Insulin Biologics and Biosimilars Market Challenges
2.3.4 Insulin Biologics and Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Insulin Biologics and Biosimilars Players by Revenue
3.1.1 Global Top Insulin Biologics and Biosimilars Players by Revenue (2018-2024)
3.1.2 Global Insulin Biologics and Biosimilars Revenue Market Share by Players (2018-2024)
3.2 Global Insulin Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Insulin Biologics and Biosimilars Revenue
3.4 Global Insulin Biologics and Biosimilars Market Concentration Ratio
3.4.1 Global Insulin Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Insulin Biologics and Biosimilars Revenue in 2022
3.5 Insulin Biologics and Biosimilars Key Players Head office and Area Served
3.6 Key Players Insulin Biologics and Biosimilars Product Solution and Service
3.7 Date of Enter into Insulin Biologics and Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Insulin Biologics and Biosimilars Breakdown Data by Type
4.1 Global Insulin Biologics and Biosimilars Historic Market Size by Type (2018-2024)
4.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Type (2024-2029)
5 Insulin Biologics and Biosimilars Breakdown Data by Application
5.1 Global Insulin Biologics and Biosimilars Historic Market Size by Application (2018-2024)
5.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Insulin Biologics and Biosimilars Market Size (2018-2029)
6.2 North America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Insulin Biologics and Biosimilars Market Size by Country (2018-2024)
6.4 North America Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Insulin Biologics and Biosimilars Market Size (2018-2029)
7.2 Europe Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Insulin Biologics and Biosimilars Market Size by Country (2018-2024)
7.4 Europe Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Insulin Biologics and Biosimilars Market Size (2018-2029)
8.2 Asia-Pacific Insulin Biologics and Biosimilars Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2018-2024)
8.4 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Insulin Biologics and Biosimilars Market Size (2018-2029)
9.2 Latin America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Insulin Biologics and Biosimilars Market Size by Country (2018-2024)
9.4 Latin America Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Insulin Biologics and Biosimilars Market Size (2018-2029)
10.2 Middle East & Africa Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2018-2024)
10.4 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Detail
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Insulin Biologics and Biosimilars Introduction
11.1.4 Novo Nordisk Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.1.5 Novo Nordisk Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Insulin Biologics and Biosimilars Introduction
11.2.4 Eli Lilly Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.2.5 Eli Lilly Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Insulin Biologics and Biosimilars Introduction
11.3.4 Sanofi Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.3.5 Sanofi Recent Development
11.4 Gan&Lee
11.4.1 Gan&Lee Company Detail
11.4.2 Gan&Lee Business Overview
11.4.3 Gan&Lee Insulin Biologics and Biosimilars Introduction
11.4.4 Gan&Lee Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.4.5 Gan&Lee Recent Development
11.5 Tonghua Dongbao
11.5.1 Tonghua Dongbao Company Detail
11.5.2 Tonghua Dongbao Business Overview
11.5.3 Tonghua Dongbao Insulin Biologics and Biosimilars Introduction
11.5.4 Tonghua Dongbao Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.5.5 Tonghua Dongbao Recent Development
11.6 United Laboratory
11.6.1 United Laboratory Company Detail
11.6.2 United Laboratory Business Overview
11.6.3 United Laboratory Insulin Biologics and Biosimilars Introduction
11.6.4 United Laboratory Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.6.5 United Laboratory Recent Development
11.7 Geropharm
11.7.1 Geropharm Company Detail
11.7.2 Geropharm Business Overview
11.7.3 Geropharm Insulin Biologics and Biosimilars Introduction
11.7.4 Geropharm Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.7.5 Geropharm Recent Development
11.8 Biocon
11.8.1 Biocon Company Detail
11.8.2 Biocon Business Overview
11.8.3 Biocon Insulin Biologics and Biosimilars Introduction
11.8.4 Biocon Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.8.5 Biocon Recent Development
11.9 Wockhardt
11.9.1 Wockhardt Company Detail
11.9.2 Wockhardt Business Overview
11.9.3 Wockhardt Insulin Biologics and Biosimilars Introduction
11.9.4 Wockhardt Revenue in Insulin Biologics and Biosimilars Business (2018-2024)
11.9.5 Wockhardt Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Insulin Biologics
Table 3. Key Players of Insulin Biosimilars
Table 4. Global Insulin Biologics and Biosimilars Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 5. Global Insulin Biologics and Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Insulin Biologics and Biosimilars Market Size by Region (2018-2024) & (US$ Million)
Table 7. Global Insulin Biologics and Biosimilars Market Share by Region (2018-2024)
Table 8. Global Insulin Biologics and Biosimilars Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 9. Global Insulin Biologics and Biosimilars Market Share by Region (2024-2029)
Table 10. Insulin Biologics and Biosimilars Market Trends
Table 11. Insulin Biologics and Biosimilars Market Drivers
Table 12. Insulin Biologics and Biosimilars Market Challenges
Table 13. Insulin Biologics and Biosimilars Market Restraints
Table 14. Global Insulin Biologics and Biosimilars Revenue by Players (2018-2024) & (US$ Million)
Table 15. Global Insulin Biologics and Biosimilars Market Share by Players (2018-2024)
Table 16. Global Top Insulin Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin Biologics and Biosimilars as of 2022)
Table 17. Ranking of Global Top Insulin Biologics and Biosimilars Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Insulin Biologics and Biosimilars Revenue (CR5 and HHI) & (2018-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Insulin Biologics and Biosimilars Product Solution and Service
Table 21. Date of Enter into Insulin Biologics and Biosimilars Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Insulin Biologics and Biosimilars Market Size by Type (2018-2024) & (US$ Million)
Table 24. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2018-2024)
Table 25. Global Insulin Biologics and Biosimilars Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 26. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2024-2029)
Table 27. Global Insulin Biologics and Biosimilars Market Size by Application (2018-2024) & (US$ Million)
Table 28. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2018-2024)
Table 29. Global Insulin Biologics and Biosimilars Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 30. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2024-2029)
Table 31. North America Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 32. North America Insulin Biologics and Biosimilars Market Size by Country (2018-2024) & (US$ Million)
Table 33. North America Insulin Biologics and Biosimilars Market Size by Country (2024-2029) & (US$ Million)
Table 34. Europe Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. Europe Insulin Biologics and Biosimilars Market Size by Country (2018-2024) & (US$ Million)
Table 36. Europe Insulin Biologics and Biosimilars Market Size by Country (2024-2029) & (US$ Million)
Table 37. Asia-Pacific Insulin Biologics and Biosimilars Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2018-2024) & (US$ Million)
Table 39. Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 41. Latin America Insulin Biologics and Biosimilars Market Size by Country (2018-2024) & (US$ Million)
Table 42. Latin America Insulin Biologics and Biosimilars Market Size by Country (2024-2029) & (US$ Million)
Table 43. Middle East & Africa Insulin Biologics and Biosimilars Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2018-2024) & (US$ Million)
Table 45. Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2024-2029) & (US$ Million)
Table 46. Novo Nordisk Company Detail
Table 47. Novo Nordisk Business Overview
Table 48. Novo Nordisk Insulin Biologics and Biosimilars Product
Table 49. Novo Nordisk Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 50. Novo Nordisk Recent Development
Table 51. Eli Lilly Company Detail
Table 52. Eli Lilly Business Overview
Table 53. Eli Lilly Insulin Biologics and Biosimilars Product
Table 54. Eli Lilly Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 55. Eli Lilly Recent Development
Table 56. Sanofi Company Detail
Table 57. Sanofi Business Overview
Table 58. Sanofi Insulin Biologics and Biosimilars Product
Table 59. Sanofi Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 60. Sanofi Recent Development
Table 61. Gan&Lee Company Detail
Table 62. Gan&Lee Business Overview
Table 63. Gan&Lee Insulin Biologics and Biosimilars Product
Table 64. Gan&Lee Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 65. Gan&Lee Recent Development
Table 66. Tonghua Dongbao Company Detail
Table 67. Tonghua Dongbao Business Overview
Table 68. Tonghua Dongbao Insulin Biologics and Biosimilars Product
Table 69. Tonghua Dongbao Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 70. Tonghua Dongbao Recent Development
Table 71. United Laboratory Company Detail
Table 72. United Laboratory Business Overview
Table 73. United Laboratory Insulin Biologics and Biosimilars Product
Table 74. United Laboratory Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 75. United Laboratory Recent Development
Table 76. Geropharm Company Detail
Table 77. Geropharm Business Overview
Table 78. Geropharm Insulin Biologics and Biosimilars Product
Table 79. Geropharm Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 80. Geropharm Recent Development
Table 81. Biocon Company Detail
Table 82. Biocon Business Overview
Table 83. Biocon Insulin Biologics and Biosimilars Product
Table 84. Biocon Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 85. Biocon Recent Development
Table 86. Wockhardt Company Detail
Table 87. Wockhardt Business Overview
Table 88. Wockhardt Insulin Biologics and Biosimilars Product
Table 89. Wockhardt Revenue in Insulin Biologics and Biosimilars Business (2018-2024) & (US$ Million)
Table 90. Wockhardt Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Insulin Biologics and Biosimilars Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Insulin Biologics and Biosimilars Market Share by Type: 2022 VS 2029
Figure 3. Insulin Biologics Features
Figure 4. Insulin Biosimilars Features
Figure 5. Global Insulin Biologics and Biosimilars Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 6. Global Insulin Biologics and Biosimilars Market Share by Application: 2022 VS 2029
Figure 7. Hospital Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Other Case Studies
Figure 10. Insulin Biologics and Biosimilars Report Years Considered
Figure 11. Global Insulin Biologics and Biosimilars Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 12. Global Insulin Biologics and Biosimilars Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Insulin Biologics and Biosimilars Market Share by Region: 2022 VS 2029
Figure 14. Global Insulin Biologics and Biosimilars Market Share by Players in 2022
Figure 15. Global Top Insulin Biologics and Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin Biologics and Biosimilars as of 2022)
Figure 16. The Top 10 and 5 Players Market Share by Insulin Biologics and Biosimilars Revenue in 2022
Figure 17. North America Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 18. North America Insulin Biologics and Biosimilars Market Share by Country (2018-2029)
Figure 19. United States Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. Canada Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Europe Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Insulin Biologics and Biosimilars Market Share by Country (2018-2029)
Figure 23. Germany Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. France Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. U.K. Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Italy Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Russia Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Nordic Countries Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Asia-Pacific Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Insulin Biologics and Biosimilars Market Share by Region (2018-2029)
Figure 31. China Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Japan Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. South Korea Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Southeast Asia Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. India Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Australia Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Latin America Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Insulin Biologics and Biosimilars Market Share by Country (2018-2029)
Figure 39. Mexico Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Brazil Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Middle East & Africa Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Insulin Biologics and Biosimilars Market Share by Country (2018-2029)
Figure 43. Turkey Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Saudi Arabia Insulin Biologics and Biosimilars Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Novo Nordisk Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 46. Eli Lilly Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 47. Sanofi Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 48. Gan&Lee Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 49. Tonghua Dongbao Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 50. United Laboratory Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 51. Geropharm Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 52. Biocon Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 53. Wockhardt Revenue Growth Rate in Insulin Biologics and Biosimilars Business (2018-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed